Trials / Not Yet Recruiting
Not Yet RecruitingNCT06575049
Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.
Conditions
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2025-08-30
- Completion
- 2026-02-20
- First posted
- 2024-08-28
- Last updated
- 2024-09-19
Source: ClinicalTrials.gov record NCT06575049. Inclusion in this directory is not an endorsement.